TY - JOUR
T1 - Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification
AU - SYNAPS Study Group
AU - Schottlaender, Lucia V.
AU - Abeti, Rosella
AU - Jaunmuktane, Zane
AU - Macmillan, Carol
AU - Chelban, Viorica
AU - O'Callaghan, Benjamin
AU - McKinley, John
AU - Maroofian, Reza
AU - Efthymiou, Stephanie
AU - Athanasiou-Fragkouli, Alkyoni
AU - Forbes, Raeburn
AU - Soutar, Marc P.M.
AU - Livingston, John H.
AU - Kalmar, Bernardett
AU - Swayne, Orlando
AU - Hotton, Gary
AU - Groppa, Stanislav
AU - Karashova, Blagovesta Marinova
AU - Nachbauer, Wolfgang
AU - Boesch, Sylvia
AU - Arning, Larissa
AU - Timmann, Dagmar
AU - Cormand, Bru
AU - Pérez-Dueñas, Belen
AU - Di Rosa, Gabriella
AU - Goraya, Jatinder S.
AU - Sultan, Tipu
AU - Mine, Jun
AU - Avdjieva, Daniela
AU - Kathom, Hadil
AU - Tincheva, Radka
AU - Banu, Selina
AU - Pineda-Marfa, Mercedes
AU - Veggiotti, Pierangelo
AU - Ferrari, Michel D.
AU - Verrotti, Alberto
AU - Marseglia, Giangluigi
AU - Savasta, Salvatore
AU - García-Silva, Mayte
AU - Ruiz, Alfons Macaya
AU - Garavaglia, Barbara
AU - Borgione, Eugenia
AU - Portaro, Simona
AU - Sanchez, Benigno Monteagudo
AU - Boles, Richard
AU - Papacostas, Savvas
AU - Vikelis, Michail
AU - Papanicolaou, Eleni Zamba
AU - Dardiotis, Efthymios
AU - Kirmani, Salman
N1 - Funding Information:
We are grateful to the patients for their essential help. We are grateful for the funding support from The Medical Research Council (MRC) ( MR/S01165X/1 , MR/S005021/1 ), The Wellcome Trust ( Synaptopathies Strategic Award , WT093205MA , WT104033AIA ), The Rosetree Trust , Ataxia UK , The MSA Trust , Brain Research UK , Sparks GOSH Charity , Muscular Dystrophy UK (MDUK), and Muscular Dystrophy Association (MDA USA). We also thank James Polke and Conceição Bettencourt for assistance with the text and interpretation. S.B. and H.H. are partly funded by the National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre and Dementia Biomedical Research Unit . J.R.M.deO. receives funding from CNP , CAPES , and DECIT-MS . We thank Joanne Lau for technical support. This research was also conducted as part of the Queen Square Genomics group at UCL, supported by the National Institute for Health Research (NIHR) award to UCLH NHS Trust/UCL Biomedical Research Centre (BRC).
Funding Information:
We are grateful to the patients for their essential help. We are grateful for the funding support from The Medical Research Council (MRC) (MR/S01165X/1, MR/S005021/1), The Wellcome Trust (Synaptopathies Strategic Award, WT093205MA, WT104033AIA), The Rosetree Trust, Ataxia UK, The MSA Trust, Brain Research UK, Sparks GOSH Charity, Muscular Dystrophy UK (MDUK), and Muscular Dystrophy Association (MDA USA). We also thank James Polke and Conceição Bettencourt for assistance with the text and interpretation. S.B. and H.H. are partly funded by the National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre and Dementia Biomedical Research Unit. J.R.M.deO. receives funding from CNP, CAPES, and DECIT-MS. We thank Joanne Lau for technical support. This research was also conducted as part of the Queen Square Genomics group at UCL, supported by the National Institute for Health Research (NIHR) award to UCLH NHS Trust/UCL Biomedical Research Centre (BRC).
Publisher Copyright:
© 2020 The Authors
PY - 2020/3/5
Y1 - 2020/3/5
N2 - Primary familial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by a combination of neurological, psychiatric, and cognitive decline associated with calcium deposition on brain imaging. To date, mutations in five genes have been linked to PFBC. However, more than 50% of individuals affected by PFBC have no molecular diagnosis. We report four unrelated families presenting with initial learning difficulties and seizures and later psychiatric symptoms, cerebellar ataxia, extrapyramidal signs, and extensive calcifications on brain imaging. Through a combination of homozygosity mapping and exome sequencing, we mapped this phenotype to chromosome 21q21.3 and identified bi-allelic variants in JAM2. JAM2 encodes for the junctional-adhesion-molecule-2, a key tight-junction protein in blood-brain-barrier permeability. We show that JAM2 variants lead to reduction of JAM2 mRNA expression and absence of JAM2 protein in patient's fibroblasts, consistent with a loss-of-function mechanism. We show that the human phenotype is replicated in the jam2 complete knockout mouse (jam2 KO). Furthermore, neuropathology of jam2 KO mouse showed prominent vacuolation in the cerebral cortex, thalamus, and cerebellum and particularly widespread vacuolation in the midbrain with reactive astrogliosis and neuronal density reduction. The regions of the human brain affected on neuroimaging are similar to the affected brain areas in the myorg PFBC null mouse. Along with JAM3 and OCLN, JAM2 is the third tight-junction gene in which bi-allelic variants are associated with brain calcification, suggesting that defective cell-to-cell adhesion and dysfunction of the movement of solutes through the paracellular spaces in the neurovascular unit is a key mechanism in CNS calcification.
AB - Primary familial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by a combination of neurological, psychiatric, and cognitive decline associated with calcium deposition on brain imaging. To date, mutations in five genes have been linked to PFBC. However, more than 50% of individuals affected by PFBC have no molecular diagnosis. We report four unrelated families presenting with initial learning difficulties and seizures and later psychiatric symptoms, cerebellar ataxia, extrapyramidal signs, and extensive calcifications on brain imaging. Through a combination of homozygosity mapping and exome sequencing, we mapped this phenotype to chromosome 21q21.3 and identified bi-allelic variants in JAM2. JAM2 encodes for the junctional-adhesion-molecule-2, a key tight-junction protein in blood-brain-barrier permeability. We show that JAM2 variants lead to reduction of JAM2 mRNA expression and absence of JAM2 protein in patient's fibroblasts, consistent with a loss-of-function mechanism. We show that the human phenotype is replicated in the jam2 complete knockout mouse (jam2 KO). Furthermore, neuropathology of jam2 KO mouse showed prominent vacuolation in the cerebral cortex, thalamus, and cerebellum and particularly widespread vacuolation in the midbrain with reactive astrogliosis and neuronal density reduction. The regions of the human brain affected on neuroimaging are similar to the affected brain areas in the myorg PFBC null mouse. Along with JAM3 and OCLN, JAM2 is the third tight-junction gene in which bi-allelic variants are associated with brain calcification, suggesting that defective cell-to-cell adhesion and dysfunction of the movement of solutes through the paracellular spaces in the neurovascular unit is a key mechanism in CNS calcification.
KW - Fahr disease
KW - JAM2
KW - JAM3
KW - MYORG
KW - OCLN
KW - SLC20A2
KW - familial idiopathic basal ganglia calcification
KW - knock out mouse model
KW - primary familial brain calcification
KW - recessive brain calcification
UR - http://www.scopus.com/inward/record.url?scp=85080107983&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2020.02.007
DO - 10.1016/j.ajhg.2020.02.007
M3 - Article
AN - SCOPUS:85080107983
SN - 0002-9297
VL - 106
SP - 412
EP - 421
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 3
ER -